These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 18387078

  • 1. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.
    Bartley PC, Bogoev M, Larsen J, Philotheou A.
    Diabet Med; 2008 Apr; 25(4):442-9. PubMed ID: 18387078
    [Abstract] [Full Text] [Related]

  • 2. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.
    Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
    [Abstract] [Full Text] [Related]

  • 3. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
    Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA.
    Diabetologia; 2004 Apr; 47(4):622-9. PubMed ID: 15298338
    [Abstract] [Full Text] [Related]

  • 4. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W.
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [Abstract] [Full Text] [Related]

  • 5. Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial.
    Thalange N, Bereket A, Larsen J, Hiort LC, Peterkova V.
    Diabet Med; 2013 Feb; 30(2):216-25. PubMed ID: 23094597
    [Abstract] [Full Text] [Related]

  • 6. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin.
    De Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E, Elte JW.
    Diabetes Obes Metab; 2005 Jan; 7(1):73-82. PubMed ID: 15642078
    [Abstract] [Full Text] [Related]

  • 7. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K.
    Cochrane Database Syst Rev; 2020 Nov 09; 11(11):CD005613. PubMed ID: 33166419
    [Abstract] [Full Text] [Related]

  • 8. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin.
    Pieber TR, Draeger E, Kristensen A, Grill V.
    Diabet Med; 2005 Jul 09; 22(7):850-7. PubMed ID: 15975098
    [Abstract] [Full Text] [Related]

  • 9. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug 09; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 10. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
    Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E.
    Diabetes Care; 2003 Mar 09; 26(3):590-6. PubMed ID: 12610006
    [Abstract] [Full Text] [Related]

  • 11. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov 09; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 12. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
    Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J.
    Diabet Med; 2007 Jan 09; 24(1):27-34. PubMed ID: 17227321
    [Abstract] [Full Text] [Related]

  • 13. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S, Koenen C, Bode B.
    Clin Ther; 2009 Oct 09; 31(10):2086-97. PubMed ID: 19922879
    [Abstract] [Full Text] [Related]

  • 14. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
    Standl E, Lang H, Roberts A.
    Diabetes Technol Ther; 2004 Oct 09; 6(5):579-88. PubMed ID: 15628811
    [Abstract] [Full Text] [Related]

  • 15. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes.
    Kølendorf K, Ross GP, Pavlic-Renar I, Perriello G, Philotheou A, Jendle J, Gall MA, Heller SR.
    Diabet Med; 2006 Jul 09; 23(7):729-35. PubMed ID: 16842476
    [Abstract] [Full Text] [Related]

  • 16. Insulin detemir: a review of its use in the management of diabetes mellitus.
    Keating GM.
    Drugs; 2012 Dec 03; 72(17):2255-87. PubMed ID: 23110609
    [Abstract] [Full Text] [Related]

  • 17. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.
    Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B, PREFER Study Group.
    Diabetes Obes Metab; 2009 Jan 03; 11(1):45-52. PubMed ID: 18643839
    [Abstract] [Full Text] [Related]

  • 18. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes.
    Umpierrez GE, Hor T, Smiley D, Temponi A, Umpierrez D, Ceron M, Munoz C, Newton C, Peng L, Baldwin D.
    J Clin Endocrinol Metab; 2009 Feb 03; 94(2):564-9. PubMed ID: 19017758
    [Abstract] [Full Text] [Related]

  • 19. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR, Gilbert RE, Yue DK.
    Intern Med J; 2005 Sep 03; 35(9):536-42. PubMed ID: 16105155
    [Abstract] [Full Text] [Related]

  • 20. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials.
    Garber AJ, Clauson P, Pedersen CB, Kølendorf K.
    J Am Geriatr Soc; 2007 Nov 03; 55(11):1735-40. PubMed ID: 17979896
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.